Based on data from an interim analysis of the ongoing Phase 3 study, the European Medicines Agency validated a Marketing Authorization Application in the EU for valoctocogene roxaparvovec, and the review process has begun.If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe intellectual disability, seizures, tremors, behavioral problems and psychiatric symptoms.